Crimson Publishers Publish With Us Reprints e-Books Video articles


Developments in Clinical & Medical Pathology

Advances in Ex vivo Cell Screening Methodologies for Clinical Therapy Guidance to Leukemic Patients

  • Open or Close Aditya Kulkarni*

    Scientist, Baylor College of Medicine, USA

    *Corresponding author: Aditya Kulkarni, Scientist, Baylor College of Medicine, Lantern Pharma, Inc, Houston TX, USA

Submission: February 1, 2018;Published: April 11, 2018

Volume1 Issue1
April 2018


Advances in liquid biopsy handling and processing have reinvigorated interest in ex vivo screening methods for drug discovery and as an emerging feature of patient care in the field of hematological cancers. Treatments based on ex vivo assays are gaining traction since they have demonstrated new benefits using approved drugs to treat leukemia and associated cancers. Various unique assay platforms, specifically designed to predict therapeutic response in leukemic patients within a clinically actionable time frame, have shown high accuracy, reproducibility and highthroughput potential and promise to serve as a decision support system for therapeutic management of multiple hematologic malignancies.

Keywords: Hematologic malignancy; Ex vivo tissue culture; Tumor microenvironment; Clinical therapy guidance; AML

Get access to the full text of this article